Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response (DDR) Pathway Deficient Neoplasms (UF-STO-ETI-001)

NCT03207347 is registered in ClinicalTrials.gov with University of Florida as lead sponsor.

NCT NCT03207347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03207347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response (DDR) Pathway Deficient Neoplasms (UF-STO-ETI-001)
Lead sponsor
University of Florida
Phase
Phase 2
Overall status
Completed
Start date
August 13, 2018
Completion date
August 30, 2022
Enrollment
37 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma, mesothelioma, renal cell carcinoma, uveal melanoma